Collegium Pharmaceutical, Inc. Names Douglas Carlson to Vice President of Business Development
Published: Apr 03, 2013
CANTON, Mass., April 3, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has hired Douglas Carlson in the newly-created position of Vice President of Business Development.
Doug previously held the position of Senior Director, Business Development at BTG International Inc., where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG International, Doug spent nearly five years at Ovation Pharmaceuticals, Inc. where he advanced from Manager of Business Development to Senior Director of Corporate Business Development and Strategy, and played a pivotal role in the sale of Ovation to H. Lundbeck A/S resulting in a $900 million acquisition. Prior to Ovation, Doug was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Doug started his career in the healthcare investing banking group SG Cowen & Co. He received a Bachelor of Arts degree in American Studies from Trinity College in Hartford, Connecticut and completed a post-graduate advanced studies program at Oxford University.
"Collegium's lead development program, Oxycodone DETERx®, leverages the Company's abuse-deterrent technology platform in an area with significant unmet medical need. I am incredibly excited to be joining Collegium as the Company brings its first product closer to FDA approval," states Doug Carlson.
"As we rapidly advance Oxycodone DETERx® towards an NDA filing within the next 12 months, we will be initiating a process to identify potential commercial partners for both the U.S. and international markets. We are excited to have a person with Doug's experience and background joining the team at this important time for the Company," states Michael Heffernan, CEO of Collegium.
About DETERx® Technology
The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. COL-003 is the first of a number of product candidates using the DETERx® platform.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.
Michael Heffernan, President
Collegium Pharmaceutical, Inc.
SOURCE Collegium Pharmaceutical, Inc.